Skip to content
DataLookout
Menu

NCT07291232

A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity

StatusActive, Not Recruiting
PhasePhase 1
SponsorAbbVie
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary endpoints: details revised at 1 of 15 entries Show 4 more changesShow less
    • Eligibility criteria expanded, about 5 words
    • Enrollment closed, study ongoing
    • Primary and study completion dates: Mar 2027 to Apr 2027
    • Site details revised at 2 of 2 sites
  2. Notable Enrollment increased: 48 → 80 participants
    • Primary and study completion pushed from Oct 2026 to Mar 2027
    • Trial arms changed: 4 → 8
    • Study sites revised (2)
    v4
  3. Minor Study sites: 1 to 2v3
  4. Notable Enrollment target: 96 to 48
    • Study arms: 6 to 4
    v2
  5. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Number of Participants with Adverse Events (AEs)
Timeframe: Up to approximately 194 days
Number of Participants with Abnormal Change From Baseline in Vital Sign Measurements
Timeframe: Up to approximately 194 days
Number of Participants with Change from Baseline in Electrocardiogram (ECG)
Timeframe: Up to approximately 194 days
Number of Participants with Abnormal Change in Clinical Laboratory Test Results Like Hematology will be Assessed
Timeframe: Up to approximately 194 days
Maximum Observed Plasma Concentration (Cmax) of ABBV-295
Timeframe: Up to approximately 194 days
Time to Cmax (Tmax) of ABBV-295
Timeframe: Up to approximately 194 days
Trough plasma concentration (Ctrough) of ABBV-295
Timeframe: Up to approximately 194 days
Apparent terminal phase elimination rate constant (BETA) of ABBV-295
Timeframe: Up to approximately 194 days
Terminal phase elimination half-life (t1/2) of ABBV-295
Timeframe: Up to approximately 194 days
Area under the plasma concentration-time curve (AUC) of ABBV-295
Timeframe: Up to approximately 194 days
Area under the plasma concentration-time curve over the dosing interval (AUCtau) of ABBV-295
Timeframe: Up to approximately 194 days
Dose Normalized Cmax of ABBV-295
Timeframe: Up to approximately 194 days
Dose Normalized AUC of ABBV-295
Timeframe: Up to approximately 194 days
Incidence of Anti-Drug Antibodies (ADAs)
Timeframe: Up to approximately 194 days
Percent Change in Body Weight From Baseline
Timeframe: Up to approximately 194 days

Arms and interventions

ABBV-295 or Placebo-Group 1Experimental

Participants will receive subcutaneous doses of ABBV-295 or Placebo for 13 weeks.

ABBV-295 or Placebo-Group 2Experimental

Participants will receive subcutaneous doses of ABBV-295 or Placebo for 13 weeks.

ABBV-295 or Placebo-Group 3Experimental

Participants will receive subcutaneous doses of ABBV-295 or Placebo for 13 weeks.

ABBV-295 or Placebo-Group 3 ExtensionExperimental

Participants will receive subcutaneous doses of ABBV-295 or Placebo for 13 weeks or 20 weeks.

ABBV-295 or Placebo-Group 4Experimental

Participants will receive subcutaneous doses of ABBV-295 or Placebo for 13 weeks.

ABBV-295 or Placebo-Group 4 ExtensionExperimental

Participants will receive subcutaneous doses of ABBV-295 or Placebo for 13 weeks or 20 weeks.

ABBV-295 or Placebo-Group 5Experimental

Participants will receive subcutaneous doses of ABBV-295 or Placebo for 20 weeks.

ABBV-295 or Placebo-Group 6Experimental

Participants will receive subcutaneous doses of ABBV-295 or Placebo for 20 weeks.

Drugs: ABBV-295, Placebo

Sites

2 sites in 1 country